The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

Yang, Jiarui; Liang, Hao; Hu, Kunpeng; Xiong, Zhiyong; Cao, Mingbo; Zhong, Zhaozhong; Yao, Zhicheng; Deng, Meihai

doi:10.1186/s12935-021-01790-6

Table 2 Characteristics of the included studies

From: The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

Author, year	Country	Study design	Variety of analysis	Intervention	Case (n)	BCLC	AFP	Age (year)	Male	Curative resection	Follow up months	Outcome	NOS score
Xiao, 2019 [14]	China	RS (PSM)	MA	Re-resection/RFA	49	BCLC B-C 22	> 200 32.7%	NR	43	yes	84	OS	5
Xiao, 2019 [14]	China	RS (PSM)	MA	Pa-TACE: carboplatin 300 mg, epirubicin 50 mg, mytomycin C 8 mg	49	BCLC B-C 25	> 200 38.8%	NR	46	yes	84	OS	5
Wang, 2018 [11]	China	RS (PSM)	MA	Conservation	57	BCLC B 10	> 200 40%	56 ± 10	51	yes	60	OS, RFS	7
Wang, 2018 [11]	China	RS (PSM)	MA	Pa-TACE: fluorouracil 750 mg, epirubicin 40 mg or pharmorubici 40 mg	57	BCLC B 11	> 200 44%	55 ± 11	47	yes	60	OS, RFS	7
Wang, 2019 [12]	China	RS (PSM)	MA	Radiotherapy: 54–60 Gy	46	NR	> 400 22%	50.98 ± 10.53	43	yes	100	OS, RFS	8
Wang, 2019 [12]	China	RS (PSM)	MA	Pa-TACE: doxorubicin 20–30 mg	46	NR	> 400 15%	51.52 ± 11.40	37	yes	100	OS, RFS	8
Wei, 2018 [15]	China	RCT	UA	Conservation	118	NR	≥ 25 69.5%	48.5 (18–74)	106	yes	72	OS. RFS
Wei, 2018 [15]	China	RCT	UA	Pa-TACE: carboplatin 200 mg, mitomycin 6 mg, epirubicin 40 mg	116	NR	≥ 25 68.1%	44 (18–75)	106	yes	72	OS, RFS
Wang, 2018 [16]	China	RS	MA	Conservation	84	NR	367.45 ± 474.58	54.49 ± 10.18	76	yes	84	OS, RFS	8
Wang, 2018 [16]	China	RS	MA	Pa-TACE: doxorubicin 10 mg or pharmorubicin 20–40 mg	44	NR	357 ± 444.12	52.07 ± 7.27	42	yes	84	OS, RFS	8
Ye, 2017 [17]	China	RS	MA	Conservation	174	BCLC B 47	> 400 48.9%	> 60 19.5%	150	yes	60	OS, RFS	8
Ye, 2017 [17]	China	RS	MA	Pa-TACE: lobaplatin 50 mg, raltitrexed 4 mg	86	BCLC B 16	> 400 43%	> 60 15.1%	75	yes	60	OS, RFS	8
Wang, 2017 [13]	China	RS	MA	Conservation	50	NR	> 400 36%	57.22 ± 11.14	5	yes	60	OS, RFS	7
				Pa-TACE: adriamycin 20–30 mg	42	NR	> 400 40.5%	51.38 ± 10.89	8	yes	60	OS, RFS
				Radiotherapy: 54–60 Gy	44	NR	> 400 22.7%	51.32 ± 11.21	5	yes	60	OS, RFS
Liu, 2016 [18]	China	RS	UA	Conservation	159	BCLC B 12	> 400 57.2%	53 ± 11.8	125	yes	60	OS, RFS	8
Liu, 2016 [18]	China	RS	UA	Pa-TACE: fluorouracil 750 mg, epirubicin 40 mg or pharmorubici 40 mg	137	BCLC B 16	> 400 49.6%	49 ± 10.6	134	yes	60	OS, RFS	8
Sun, 2015 [19]	China	RS	MA	Conservation	185	BCLC A/B 98	> 400 49.2%	49.91 ± 0.72	167	yes	120	OS, RFS	8
Sun, 2015 [19]	China	RS	MA	Pa-TACE: doxorubicin 10 mg or pharmorubicin 20–40 mg	137	BCLC A/b 76	> 400 42.3%	48.88 ± 0.87	120	yes	120	OS, RFS	8
Liu, 2016 [20]	China	RS	UA	Conservation	26	NR	NR	NR	NR	yes	40	RFS	5
Liu, 2016 [20]	China	RS	UA	Pa-TACE: fluorouracil 1000 mg, oxaliplatin 100 mg, epirubicin 40–60 mg	24	NR	NR	NR	NR	yes	40	RFS	5
Jin, 2014 [21]	Korea	RS	UA	Resection/RFA	8	NR	NR	NR	NR	yes	96	OS	5
Jin, 2014 [21]	Korea	RS	UA	Pa-TACE: cisplatin 0.5 mg	23	NR	NR	NR	NR	yes	96	OS	5
Huang, 2019 [23]	China	RS	MA	Conservation	33	BCLC B 12.5%	> 400 42.42%	51.52 ± 11.87	30	yes	72	OS, RFS	7
Huang, 2019 [23]	China	RS	MA	Sorafenib	16	BCLC B 12.1%	> 400 50%	52.25 ± 11.94	12	yes	72	OS, RFS	7
Qi, 2018 [22]	China	RS	UA	Conservation	109	BCLC B 33	> 400 45.8%	NR	93	yes	36	OS, RFS	7
Qi, 2018 [22]	China	RS	UA	TACE:lobaplatin (25–100 mg) + pharmorubici (10–50 mg)	91	BCLC B 37	> 400 48.4%	NR	78	yes	36	OS, RFS	7

Pa-TACE postoperative adjuvant transarterial chemoembolization, PSM propensity score matching, RCT randomized clinical trial, RFA radiofrequency ablation ablation, MA multivariate analysis, UA univariate analysis, RS retrospective study

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com

Cancer Cell International

Contact us